help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on October 2, 2003, doi:10.1164/rccm.200304-542OC
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200304-542OCv1
168/12/1506    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Senn, O.
Right arrow Articles by Bloch, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Senn, O.
Right arrow Articles by Bloch, K. E.
American Journal of Respiratory and Critical Care Medicine Vol 168. pp. 1506-1511, (2003)
© 2003 American Thoracic Society

Randomized Short-term Trial of Two AutoCPAP Devices versus Fixed Continuous Positive Airway Pressure for the Treatment of Sleep Apnea

Oliver Senn, Thomas Brack, Felix Matthews, Erich W. Russi and Konrad E. Bloch

Pulmonary Division, University Hospital of Zürich, Zürich, Switzerland

Correspondence and requests for reprints should be addressed to Konrad E. Bloch, M.D., Pulmonary Division, Universitätsspital Zürich, Rämistrasse 100, CH-8091 Zürich, Switzerland. E-mail: pneubloc{at}usz.unizh.ch


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 APPENDIX:
REFERENCES
 
We evaluated the efficacy of two different continuous positive airway pressure devices with automatic mask pressure adjustment (autoCPAP) in comparison with fixed CPAP in treating obstructive sleep apnea syndrome in 29 patients. The mean (± SE) apnea–hypopnea index was 46 ± 4 per hour and the Epworth score was 14.2 ± 0.7. Patients were treated over three consecutive 1-month periods with three regimens in random order: an autoCPAP device responding to apnea–hypopnea and snoring, another autoCPAP device responding to snoring and changes in flow contour, and fixed CPAP at the 90th pressure percentile titrated by autoCPAP over 2 weeks. Allowed pressure in the autoCPAP mode was 4 to 15 cm H2O. At the end of each treatment period, symptoms, quality of life, vigilance, and nocturnal breathing disturbances were evaluated. All three treatment modalities improved symptoms, quality-of-life domains, and apnea–hypopnea index significantly and to a similar degree. Mean (± SE) maintenance-of-wakefulness time increased by 4.5 ± 1.8, 6.0 ± 1.5, and 6.1 ± 1.4 minutes with DeVilbiss AutoAdjust LT, AutoSet T, and fixed-pressure CPAP, respectively (p < 0.001 vs. baseline, p = not significant for comparisons among the three modalities). We conclude that both autoCPAP devices were equally effective as fixed-pressure CPAP in improving major outcomes during short-term therapy of sleep apnea.

Key Words: obstructive sleep apnea • autoCPAP • continuous positive airway pressure • therapy • compliance

Nocturnal application of continuous positive airway pressure (CPAP) via nasal mask is the standard therapy for the obstructive sleep apnea syndrome. Its regular use improves excessive sleepiness, cognitive performance, and quality of life (1, 2). Conventionally, the therapeutic mask pressure, i.e., the minimal pressure that eliminates abnormal respiratory events, is determined by manual titration over the course of a night in the sleep laboratory. Alternatively, automatic computer-controlled CPAP titration (autoCPAP) may be performed over one or several nights (3). AutoCPAP devices adjust pressure by feedback control according to patterns of pressure, flow, or other signals recorded during treatment. Analysis of the pressure applied during unattended autoCPAP titration may serve to determine therapeutic pressure for subsequent treatment with conventional CPAP at a fixed pressure (4, 5).

The concept of long-term CPAP treatment with a fixed mask pressure has been challenged because the pressure required to maintain upper airway patency in patients with sleep apnea varies over a night depending on body position (6), sleep state, and other factors. CPAP requirements may also change over the course of several weeks to months due to changes in upper airway properties as well as variation in body weight. This has led to the assumption that continuous adaptation of mask pressure to the actual needs of the patient by autoCPAP might improve effectiveness of CPAP therapy by preventing sleep disturbances from unnecessarily high mask pressures during major parts of the night, by enhancing comfort, and by improving treatment adherence (7). In fact, mean mask pressure applied during autoCPAP home therapy is generally lower than the pressure level prescribed in the same patients on the basis of manual titration (7, 8). Furthermore, some (7, 9) but not all studies (8) revealed a higher treatment adherence with autoCPAP as compared with conventional fixed CPAP. However, in several studies major outcomes of sleep apnea therapy, i.e., subjective sleepiness, objective vigilance, or cognitive performance, were not improved by autoCPAP compared with fixed-pressure CPAP (10, 11), or these outcomes had not been evaluated (7, 12). One report even suggests that variation in mask pressure during autoCPAP therapy might induce sleep disturbances (13). Assessment of the potential role of autoCPAP therapy in the home is further complicated by differences in technical characteristics of devices from various manufacturers as recently suggested by bench tests (14). The clinical relevance of these laboratory findings remains still uncertain.

Therefore, the purpose of the current study was to compare the efficacy of autoCPAP applied by devices from two different manufacturers with that of conventional fixed-pressure CPAP in the domiciliary therapy of patients with the obstructive sleep apnea syndrome. Subjective symptoms, quality of life, and objective vigilance were major outcomes. We employed a randomized, controlled, crossover protocol to test the hypothesis that two autoCPAP devices that incorporate different event definitions and algorithms for pressure control differ in treatment effects among each other and in comparison with conventional fixed CPAP. Some of these results have been previously reported in the form of an abstract (15).


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 APPENDIX:
REFERENCES
 
Patients
Consecutive patients with obstructive sleep apnea syndrome based on complaints of excessive sleepiness, snoring, and apnea–hypopnea index higher than 10/hour were asked to participate in the study if they were naive to CPAP therapy. Informed consent was obtained, and the protocol was approved by the hospital ethics committee.

AutoCPAP Devices
The DeVilbiss AutoAdjust LT (Sunrise Medical, Somerset, PA), and the AutoSet T (ResMed, North Ryde, Australia) were employed. The two devices differ in algorithms for pressure control. Essentially, the DeVilbiss AutoAdjust LT responds to apnea–hypopnea and snoring and the AutoSet T to apnea–hypopnea, snoring, and changes in inspiratory flow contour. Selected technical characteristics are shown in Table E1 in the online supplement. The devices were operated either in automatic mode (allowed pressure variation from 4 to 15 cm H2O) or in fixed-pressure mode at the 90th pressure percentile determined by autoCPAP during initial adaptation over 2 weeks. The same type of nasal mask was used for all patients (Mirage; ResMed).

Protocol
Patients knew that different CPAP devices and pressure settings were evaluated but were blinded to the exact study purpose and treatment modes. They were randomized to one of six treatment sequences, each comprising a 2-week adaptation period with autoCPAP treatment with either device, and, subsequently, three 1-month treatment periods with either AutoSet T in automatic mode or DeVilbis AutoAdjust LT in automatic mode, or either one of the devices in fixed-pressure mode (at the 90th percentile of pressure applied during the 2-week adaptation period) in random order. At baseline and after each 1-month period, the treatment effects were assessed.

Measurements and Outcomes
Subjective assessment.
Sleepiness and other symptoms were assessed by the Epworth sleepiness scale (16) and the modified questionnaire of Kump and coworkers (17) (see APPENDIX). Health-related quality of life was assessed by the SF-36 questionnaire (18). The perceived benefit of CPAP therapy was scored on a Likert scale extending from 1 (very disturbing) to 5 points (excellent benefit). At the end of the study, patients were asked whether they had any preference for one of the pressure settings and devices. Occurrence of side effects was noted.

Vigilance and sleep studies.
The ability to resist sleep in a darkened room was measured over four 40-minute periods on 1 day by a modified maintenance-of-wakefulness test (19) (OSLER test; Stowood Scientific Systems, Oxford, UK). The mean time until seven successive responses to a light signal were missed (sleep resistance time) (19), and the mean number of missed responses per minute were determined (20). Sleep studies were performed as described previously and detailed in the online supplement (21, 22).

Treatment data.
Daily treatment times, corresponding pressures, and occurrence of apnea–hypopnea were recorded by the autoCPAP devices.

Statistical Analysis
Data are presented as means ±SE. Effects of treatment modes, devices, and treatment order were evaluated by analysis of variance (23). Magnitudes of treatment benefit were assessed by computing effect sizes for outcome variables as ratio of the mean difference to baseline divided by the SD of the mean at baseline (24). For example, an effect size of 1 corresponds to a change of 1 SD of the sample. An effect size of 0.2 is considered small, of 0.5 moderate, and of 0.8 large (24). Characteristics of patients preferring different treatment modes were compared by Mann–Whitney U tests. Prevalence of side effects and preferences of treatment modalities were evaluated by Fisher's exact p tests. The pressures applied by different devices were compared by computing mean difference (bias) and limits of agreement (± 2 SD) (25). The statistical significance was assumed at p value less than 0.05.

Clinically relevant treatment effects were defined as changes in the Epworth score by 2 points (1), in the SF-36 vitality score by 10 points (2), and in sleep resistance time by 4 to 5 minutes (1). Power calculations indicated that with a sample size of 29, a nonsignificant result for these major outcomes (p > 0.05) was correct with a probability of 95%, 95%, and 64% (sleep resistance time of 4 minutes) or 82% (sleep resistance time of 5 minutes), respectively. Equivalence of treatment effects by the different modalities was evaluated by computing confidence intervals of differences in treatment effects according to Jones and coworkers (26) (see also methods description in the online supplement).


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 APPENDIX:
REFERENCES
 
Patients
Of 31 recruited patients, 29 completed the trial. Two patients were not able to undergo follow-up examinations, one due to lack of time and the other because he moved away. The analysis was performed on the remaining 29 patients (6 females). Their mean age (± SE) was 53 ± 2 years and their body mass index was 33.3 ± 1.3 kg/m2. The symptom scores and results of vigilance and sleep studies at baseline are listed in Table 1 for comparison with effects of the three treatment modalities. Confidence intervals of the differences in treatment effects of the three modalities are graphically presented in Figure E1 in the online supplement.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Effects of automatic and fixed-pressure cpap therapy

 
Outcomes
In a first analysis, we compared the effects of treatment with fixed-pressure mode between the AutoSet T and the DeVilbiss AutoAdjust LT. There was no statistically significant difference in any assessed outcome. Furthermore, neither was there any difference in baseline characteristics nor in any outcome of fixed CPAP therapy among patients in whom the pressure level for this modality was derived from the 90th pressure percentile of the AutoSet T and the DeVilbiss AutoAdjust LT, respectively, during the 2-week adaptation period. Therefore, the results obtained with fixed-pressure mode by the two devices were treated as one treatment modality that served as the control for comparison with results achieved by the two devices in automatic mode. These data are presented in Table 1. There was no effect of the order of applied treatment modalities for any of the assessed outcomes.

Symptoms and Subjective Assessment
Compared with baseline there was a significant and clinically relevant improvement in symptoms by all treatment modalities to a similar degree (Table 1, Figure E1 in the online supplement). This is illustrated by the mean decrease in Epworth scores of more than 5 points by all modalities and by improved symptom scores in the questionnaire of Kump and coworkers (17), indicating a higher subjectively perceived energy, a greater performance ability, and less interference of sleepiness with daily tasks. The SF-36 health transition, vitality and social functioning scores, and the mental component summary scores were also significantly improved by all treatment modalities (Table 1), whereas there was no change in other domains of the SF-36 questionnaire (data not shown).

The effect size, an indicator of the magnitude of treatment benefit, was large for Epworth scores with all three treatment modalities (24): effect sizes were 1.32 for AutoSet T in the automatic mode, 1.57 for DeVilbiss AutoAdjust LT in the automatic mode, and 1.50 for the fixed-pressure mode. Effect sizes on SF-36 vitality scores were 0.63 for AutoSet T in the automatic mode, 0.65 for DeVilbiss AutoAdjust LT in the automatic mode, and 0.78 for the fixed-pressure mode.

The overall benefit during treatment with all three modalities was equally high (Table 1). At the end of the study, all the patients were highly motivated to continue CPAP therapy. When asked whether they preferred any one of the pressure settings they had received over the course of the 3 months, 21 of the 29 patients had no preference. Four patients favored a variable pressure setting (automatic mode), whereas four other patients favored the fixed-pressure mode. As explanation for the preference, a shorter latency to fall asleep and less sleep disruption were mentioned. Seventeen patients preferred one autoCPAP device brand, 11 patients the other brand (p = not significant), and 1 patient had no preference. Details in handling, size, weight, and noise level during use were the most frequently cited reasons for the preference.

Skin irritation, air leaks, dry mouth or nose were the most frequent side effects experienced by 3 to 10 patients (10–34%) during the 3 treatment periods. The severity of side effects was mild and their prevalence differed neither among automatic or fixed-pressure CPAP modes nor among the two different devices. The details on side effects are listed in Table E2 of the online supplement.

Vigilance and Sleep Studies
The objectively measured ability to resist sleep improved significantly, independent of treatment modality. The mean improvement in sleep resistance time ranged from 4.5 to 6.1 minutes (Table 1). The effect sizes on sleep resistance time were 0.71 for AutoSet T in automatic mode, 0.57 for DeVilbiss AutoAdjust LT in automatic mode, and 0.71 for fixed-pressure mode. Correspondingly, less stimuli per minute were missed during OSLER tests with all treatment modalities as compared with baseline. The effect sizes on missed stimuli per minute were similar as those for mean sleep resistance times: 0.58 for AutoSet T in automatic mode, 0.58 for DeVilbiss AutoAdjust LT in automatic mode, and 0.62 for fixed-pressure mode. Sleep studies at the end of treatment periods confirmed that sleep-related breathing disturbances and nocturnal oxygenation were improved to a similar degree with all treatment modalities (Table 1, and Figures E1 and E2 in the online supplement).

Treatment Data
Data downloaded from CPAP devices revealed a high treatment adherence over each of the three 1-month periods with a mean nightly use of 5.5 hours during therapy in automatic mode with both devices and of 5.6 hours during therapy with fixed-pressure mode (p = not significant) (Table 1). CPAP machines were used for more than 2.5 hours per night in at least 79% of the nights. Consistent with the results of the laboratory sleep studies, which indicated effective suppression of breathing disturbances, the average apnea–hypopnea indices recorded by the autoCPAP devices over the course of home therapy were less than 10/hour (Table 1).

Mean mask pressures during months with therapy in fixed-pressure mode were 8.4 ± 0.3 cm H2O (range, 5–11 cm H2O). These pressures were higher by a mean of 1.3 and 1.9 cm H2O than the mean median values during automatic mode with the AutoSet T and DeVilbiss AutoAdjust LT, respectively (p < 0.01 for comparisons of both autoCPAP devices vs. fixed CPAP) (Table 1). On the other hand, the 95th percentile of applied pressures during automatic mode therapy with either device exceeded pressures during fixed mode therapy (Table 1). Medians and 90th percentiles of pressure applied by the two devices over the course of the months with automatic mode treatment did not statistically differ among each other. The mean difference in median pressure applied by AutoSet T minus the corresponding value for the DeVilbiss AutoAdjust LT was +0.6 (95% confidence interval, -0.2 to +1.3) cm H2O (p = not significant). The mean difference in the 90th percentile of pressure applied by the two devices was -0.1 (95% confidence interval, –0.9 to +0.8) cm H2O (p = not significant).

The variability of mask pressure during months with treatment in autoCPAP mode was quantified by the ratio of the 90th to the 50th percentile of applied pressure. This ratio differed among the two devices with greater values for the DeVilbiss AutoAdjust LT than for the AutoSet T (Table 1). We further investigated a potential effect of individual pressure requirements during autoCPAP therapy on pressure variability. We found a negative correlation among the ratio of the 90th to the 50th percentile and median pressure for AutoSet T (y = 1.55 – 0.04x, R2 = 0.41, p < 0.0005, see Figure E3 in the online supplement), indicating that in patients with higher median pressures, the variability of pressure was relatively less pronounced with this device. The corresponding correlation was not statistically significant for pressures applied by the DeVilbiss AutoAdjust LT (see Figure E3 in the online supplement).

To investigate whether pressure variability decreased over the time course of autoCPAP treatment, as suggested in a study in patients with position-dependent sleep apnea (27), the ratio of the 90th to the 50th percentile of applied pressure was compared among the 2-week adaptation period and each of the three subsequent 1-month autoCPAP treatment periods. None of these comparisons revealed any differences, suggesting that pressure variability did not change over time (see Figure E4 in the online supplement). Furthermore, neither the 90th nor the 50th pressure percentiles differed between the 2-week adaptation period and the subsequent 1-month period with the corresponding device in automatic mode (see Figure E5 in the online supplement).

A comparison among the four patients who preferred treatment in the automatic mode with the four patients who preferred treatment with the fixed-pressure mode, and with patients who did not have any preference did not reveal any statistically significant difference in body mass index, Epworth scores, sleep resistance times, and apnea–hypopnea indices at baseline (data not shown). In addition, among these patient groups, there was no difference in median applied mask pressures during automatic mode and fixed-pressure mode treatment (data not shown)or in the pressure variability during automatic mode treatment as estimated by the 90th to the 50th percentile ratio of applied pressure. This ratio was 1.38 ± 0.03 for the four patients preferring the automatic mode and 1.36 ± 0.06 for those four patients preferring fixed-pressure mode (p = not significant).


   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
APPENDIX:
REFERENCES
 
Our single-blinded, randomized crossover study revealed that autoCPAP home therapy over 1 month was equal to CPAP therapy at a fixed pressure in improving major outcomes of obstructive sleep apnea treatment such as subjective and objective sleepiness, quality of life, and nocturnal respiration. The direct comparison of two different autoCPAP devices employed in our study suggests that differences in event detection and algorithms of pressure adjustment implemented in these specific devices did not have a detectable impact on outcomes as both devices improved obstructive sleep apnea symptoms equally well.

The benefits of CPAP therapy observed in the current study with automatic and fixed-pressure mode in patients with moderate to severe obstructive sleep apnea are similar to those reported in previous studies with conventional fixed CPAP treatment (1, 2). To allow comparisons of the magnitude of treatment effects achieved in different domains we computed effect sizes. Effect sizes achieved in our patients on Epworth scores (i.e., effect sizes, 1.32–1.57), SF-36 vitality scores (effect sizes, 0.63–0.78), and performance in vigilance testing (effect sizes, 0.57–0.71 on sleep resistance time in the OSLER tests) by all three treatment modalities are moderate to large (24, 28). With a mean nightly use of 5.5 to 5.6 hours during automatic and fixed-pressure mode therapy, respectively, treatment adherence in the current study was similar to the 5.4 hours observed with fixed CPAP treatment in patients with comparable severity of the disease (1) but higher than the 2.8 hours/night found in some patients with milder sleep apnea (29).

We have performed treatment in the control period with both types of autoCPAP devices operating in fixed-pressure mode at the 90th pressure percentile titrated during 2 weeks. The 90th rather than the 95th pressure percentile was used because previous studies with the AutoSet T have revealed that the 95th pressure percentile during automatic titration was slightly higher than corresponding manually titrated pressures (by 9–11% corresponding to 0.7–1.3 cm H2O) (4, 8), whereas the 90th percentile closely approximated optimal CPAP determined during polysomnography (5). The effects we observed with fixed CPAP are similar to those achieved in previous trials using manual titration (1, 2). Others have shown that there is no systematic difference between automatic titration by AutoSet T and manual titration (5), and we found no difference between the 90th pressure percentiles applied by AutoSet T and DeVilbiss AutoAdjust (Table 1). Thus, it is unlikely that the automatic titration by a computer algorithm we used has biased our results compared with previous trials where CPAP was manually titrated by a technician during one single night in the laboratory.

Data on efficacy of home therapy over several weeks by autoCPAP devices are still scant. In one crossover trial in 10 patients, apnea–hypopnea indices recorded by AutoSet T over 2 months automatic therapy were similar to those during fixed-pressure CPAP at a manually titrated level (8). In another investigation (9), 44 patients selected according to their requirements for a high therapeutic CPAP of more than or equal to 10 cm H2O received treatment by AutoSet T in automatic mode and at the manually titrated fixed pressure, each over 6 weeks in a randomized crossover design. In that study, autoCPAP treatment was associated with improved sleep symptom scores and better SF-36 vitality and mental health scores as compared with fixed-pressure CPAP. In addition, average nightly CPAP use was reported to be greater in automatic than in fixed-pressure mode (mean average hours/night, 6.1 vs. 4.5, respectively), and median pressures were lower in automatic mode (mean median pressure, 6.9 vs. 10.7 cm H2O, respectively). There was no difference in subjective sleepiness as assessed by Epworth scores among the two treatment modes, and vigilance was not objectively assessed (9). Our data extend these findings by showing no additional benefit of autoCPAP over fixed CPAP therapy by AutoSet T regarding subjective and objective sleepiness, perceived energy, interference with daily tasks and quality of life, and treatment compliance in unselected patients requiring therapeutic pressures in the range of 5 to 11 cm H2O (Table 1).

A randomized parallel study evaluated home therapy by the DeVilbiss AutoAdjust LT in automatic and fixed-pressure mode over 3 to 6 months, respectively, in two groups of 23 and 25 patients with obstructive sleep apnea (7). Although the mean number of nights with more than 4 hours of CPAP use per night was greater in the automatic mode group than in the fixed-pressure group (6.5 vs. 5.7 nights/week), the average hours per night on CPAP did not differ among the groups. Mean mask pressure was lower in the automatic group (6.5 vs. 8.1 cm H2O). The reduction in the respiratory disturbance index during polysomnographies with the two treatment modes was similar (7). No data on sleepiness and other symptoms were provided. Our investigation closes this gap by demonstrating similar improvements of symptoms and measured sleep resistance times by the DeVilbiss AutoAdjust LT in the automatic and fixed-pressure mode (Table 1).

Our investigation is the first clinical comparison among two different brands of autoCPAP devices. We did not find any significant differences in symptoms, objectively measured vigilance, and nocturnal breathing disturbances during treatment indicating that superiority of any of the treatment modalities was unlikely (Table 1). To further analyze the question of equal efficacy we examined whether the confidence intervals of differences in various treatment effects fell within a range judged as clinically relevant (26) (see Figure E1 in the online supplement). This comparison suggested equivalent effects of the two devices operating in either automatic or fixed-pressure mode on quality of life and nocturnal breathing disturbances.

Medians and 90th percentiles of applied pressures did not statistically differ among the AutoSet T and the DeVilbiss AutoAdjust LT (Table 1). However, the variability of pressure expressed as the ratio of the 90th to the 50th percentile of applied pressure was greater for the DeVilbiss AutoAdjust LT (Table 1, Figure E3 in the online supplement). In addition, there was a negative correlation among the median applied pressure and the variability of pressure for the AutoSet T but not for the DeVilbiss AutoAdjust LT (see Figure E3 in the online supplement). Although this illustrates differences in event detection and/or algorithms of pressure adjustment between the two devices, the clinical relevance of the finding is questionable. The lack of any measurable difference in outcomes achieved by the two autoCPAP devices in automatic and fixed-pressure CPAP therapy suggests that the hypothetical advantages or disadvantages of one or the other modality are minor at best. In contrast to one report on patients with position-dependent sleep apnea (27), we did not observe a reduction in mask pressure variability with autoCPAP over the course of several weeks treatment (see Figure E4 in the online supplement).

Other autoCPAP devices than the two examined in the current study have been evaluated in few investigations (10–12, 30, 31). However, the results available to date do not allow firm conclusions on their potential role in sleep apnea therapy. In none of the studies has a clear advantage over fixed-pressure CPAP regarding major outcomes such as objective sleepiness, symptoms or quality of life been demonstrated during long-term therapy.

Conclusions
We found that autoCPAP therapy by the two evaluated devices over 1 month was highly effective in improving subjective and objective sleepiness, quality of life, and nocturnal breathing disturbances to a similar degree as with conventional fixed CPAP. There was no difference in side effects and compliance among the two autoCPAP devices and fixed CPAP. Only a minority of patients had a clear preference for one or the other treatment mode. Although the general concepts of autoCPAP are sound, detailed and specific information on operation of commercially available devices is concealed, and their specifications may be changed without notice. Therefore, as long as there is no evidence of superior efficacy of any particular device over simple and transparent fixed-pressure CPAP therapy, we would not recommend routine prescription of autoCPAP for long-term therapy of the obstructive sleep apnea syndrome.


   APPENDIX:
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 APPENDIX:
REFERENCES
 
SLEEP SYMPTOMS QUESTIONNAIRE (MODIFIED FROM REFERENCE 17)
Energy level:

"During the last week, how would you rate your level of energy?"

Likert scale (1) fresh as a daisy; (6) tired to death.

Interference with daily tasks:

"During the last week, to what extent has sleepiness interfered with your life?"

Likert scale (1) no interference; (6) totally.

Performance ability:

"During the last week, how would you rate your ability to perform tasks at home and at work?"

Likert scale (1) best: alert, concentrate, well; (6) worst: feel foggy, tired.


   FOOTNOTES
 
Supported by grants from the Lung League of Zürich, the Lung League of Schaffhausen, Lamprecht AG, Zürich, and Labhardt AG, Basel, Switzerland.

This article has an online supplement, which is accessible from this issue's table of contents online at www.atsjournals.org

Conflict of Interest Statement: O.S. has no declared conflict of interest; T.B. has no declared conflict of interest; F.M. has no declared conflict of interest; E.W.R. has no declared conflict of interest; K.E.B. has no declared conflict of interest.

Received in original form April 17, 2003; accepted in final form September 27, 2003


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 APPENDIX:
REFERENCES
 

  1. Jenkinson C, Davies RJO, Mullins R, Stradling JR. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999;353:2100–2105.[CrossRef][Medline]
  2. Montserrat JM, Ferrer M, Hernandez L, Farre R, Vilagut G, Navajas D, Badia JR, Carrasco E, de Pablo J, Ballester E. Effectiveness of CPAP treatment in daytime function in sleep apnea syndrome: a randomized controlled study with an optimized placebo. Am J Respir Crit Care Med 2001;164:608–613.[Abstract/Free Full Text]
  3. Berthon-Jones M. Feasability of a self-setting CPAP machine. Sleep 1993;16:S120–S123.[Medline]
  4. Teschler H, Berthon-Jones M, Thompson AB, Henkel A, Henry A, Konietzko N. Automated continuous positive airway pressure titration for obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1996;154:734–740.[Abstract]
  5. Lloberes P, Ballester E, Montserrat JM, Botifoll E, Ramirez A, Reolid A, Gistau C, Rodriguez-Roisin R. Comparison of manual and automatic CPAP titration in patients with sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1996;154:1755–1758.[Abstract]
  6. Jokic R, Klimaszewski A, Crossley M, Sridhar G, Fitzpatrick MF. Positional treatment vs continuous positive airway pressure in patients with positional obstructive sleep apnea syndrome. Chest 1999;115:771–781.[Abstract/Free Full Text]
  7. Konermann M, Sanner B, Vyleta M, Laschewski F, Groetz J, Sturm A, Zidek W. Use of conventional and self-adjusting nasal continuous positive airway pressure for treatment of severe obstructive sleep apnea syndrome. Chest 1998;113:714–718.[Abstract/Free Full Text]
  8. Teschler H, Wessendorf TE, Farhat AA, Konietzko N, Berthon-Jones M. Two months auto-adjusting versus conventional nCPAP for obstructive sleep apnoea syndrome. Eur Respir J 2000;15:990–995.[Abstract]
  9. Massie CA, McArdle N, Hart RW, Schmidt-Nowara WW, Lankford A, Hudgel DW, Gordon N, Douglas NJ. Comparison between automatic and fixed positive airway pressure therapy in the home. Am J Respir Crit Care Med 2002;167:20–23.
  10. Sériès F, Marc I. Efficacy of automatic continuous positive airway pressure therapy that uses an estimated required pressure in the treatment of obstructive sleep apnea syndrome. Ann Intern Med 1997;127:588–595.[Abstract/Free Full Text]
  11. Meurice J, Marc I, Sériès F. Efficacy of auto-CPAP in the treatment of obstructive sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1996;153:794–798.[Abstract]
  12. Randerath WJ, Schraeder O, Galetke W, Feldmeyer F, Ruhle KH. Autoadjusting CPAP therapy based on impedance efficacy, compliance and acceptance. Am J Respir Crit Care Med 2001;163:652–657.[Abstract/Free Full Text]
  13. Marrone O, Insalaco G, Bonsignore MR, Romano S, Salvaggio A, Bonsignore G. Sleep structure correlates of continuous positive airway pressure variations during application of an autotitrating continuous positive airway pressure machine in patients with obstructive sleep apnea syndrome. Chest 2002;121:759–767.[Abstract/Free Full Text]
  14. Farre R, Montserrat JM, Rigau J, Trepat X, Pinto P, Navajas D. Response of automatic continuous positive airway pressure devices to different sleep breathing patterns: a bench study. Am J Respir Crit Care Med 2002;166:469–473.[Abstract/Free Full Text]
  15. Senn O, Brack T, Matthews F, Russi EW, Bloch KE. Randomized controlled cross-over trial of two different auto CPAP devices for sleep apnea therapy [abstract]. Am J Respir Crit Care Med 2002;165:A724.
  16. Bloch KE, Schoch O, Zhang JN, Russi EW. German version of the Epworth Sleepiness Scale. Respiration (Herrlisheim) 1999;66:440–447.[CrossRef]
  17. Kump K, Whalen C, Tishler PV, Browner I, Ferrette V, Strohl KP, Rosenberg C, Redline S. Assessment of the validity and utility of a sleep-symptom questionnaire. Am J Respir Crit Care Med 1994;150:735–741.[Abstract]
  18. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey. Manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
  19. Bennett LS, Stradling JR, Davies RJ. A behavioural test to assess daytime sleepiness in obstructive sleep apnoea. J Sleep Res 1997;6:142–145.[Medline]
  20. Priest B, Brichard C, Aubert G, Liistro G, Rodenstein DO. Microsleep during a simplified maintenance of wakefulness test: a validation study of the OSLER test. Am J Respir Crit Care Med 2001;163:1619–1625.[Abstract/Free Full Text]
  21. Bloch KE. Polysomnography: a systematic review. Technol Health Care 1997;5:285–305.[Medline]
  22. American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999;22:667–689.[Medline]
  23. Bland M. An introduction to medical statistics. Oxford University Press, Oxford, UK. 1987.
  24. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178–S189.
  25. Bland MJ, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–310.[CrossRef][Medline]
  26. Jones B, Jarvis P, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:36–39.[Free Full Text]
  27. Series F, Marc I. Importance of sleep stage- and body position-dependence of sleep apnoea in determining benefits to auto-CPAP therapy. Eur Respir J 2001;18:170–175.[Abstract/Free Full Text]
  28. Jenkinson C, Stradling J, Petersen S. Comparison of three measures of quality of life outcome in the evaluation of continuous positive airways pressure therapy for sleep apnoea. J Sleep Res 1997;6:199–204.[CrossRef][Medline]
  29. Engleman HM, Kingshott RN, Wraith PK, Mackay TW, Deary IJ, Douglas N. Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1999;159:461–467.[Abstract/Free Full Text]
  30. Ficker JH, Wiest GH, Lehnert G, Wiest B, Hahn EG. Evaluation of an auto-CPAP device for treatment of obstructive sleep apnoea. Thorax 1998;53:643–648.[Abstract/Free Full Text]
  31. Hudgel DW, Fung C. A long-term randomized, cross-over comparison of auto-titrating and standard nasal continuous airway pressure. Sleep 2000;23:645–648.[Medline]



This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
M. H. Sanders, J. M. Montserrat, R. Farre, and R. J. Givelber
Positive Pressure Therapy: A Perspective on Evidence-based Outcomes and Methods of Application
Proceedings of the ATS, February 15, 2008; 5(2): 161 - 172.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
D. Pevernagie, J. F. Masa, J. C. Meurice, R. Farre, O. Marrone, and D. Rodenstein
Treatment of obstructive sleep-disordered breathing with positive airway pressure systems
Eur. Respir. Rev., December 1, 2007; 16(106): 125 - 131.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. Rigau, J. M. Montserrat, H. Wohrle, D. Plattner, M. Schwaibold, D. Navajas, and R. Farre
Bench model to simulate upper airway obstruction for analyzing automatic continuous positive airway pressure devices.
Chest, August 1, 2006; 130(2): 350 - 361.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
G. M. Nolan, S. Ryan, T. M. O'Connor, and W. T. McNicholas
Comparison of three auto-adjusting positive pressure devices in patients with sleep apnoea
Eur. Respir. J., July 1, 2006; 28(1): 159 - 164.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
Y. Nussbaumer, K. E. Bloch, T. Genser, and R. Thurnheer
Equivalence of Autoadjusted and Constant Continuous Positive Airway Pressure in Home Treatment of Sleep Apnea
Chest, March 1, 2006; 129(3): 638 - 643.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
O. Senn, T. Brack, E. W. Russi, and K. E. Bloch
A Continuous Positive Airway Pressure Trial as a Novel Approach to the Diagnosis of the Obstructive Sleep Apnea Syndrome
Chest, January 1, 2006; 129(1): 67 - 75.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Sleep-Disordered Breathing, Control of Breathing, Respiratory Muscles, Pulmonary Function Testing in AJRCCM 2003
Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 254 - 264.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200304-542OCv1
168/12/1506    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Senn, O.
Right arrow Articles by Bloch, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Senn, O.
Right arrow Articles by Bloch, K. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2003 American Thoracic Society